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Summary.-The effect of 16,16-dimethyl-PGE2-methyl ester (di-M-PGE2), a long-
acting synthetic analogue of prostaglandin E2, on the replication of Friend erythro-
leukaemia cells (FLC) in vivo has been studied. Pre-treatment in vitro of both
undifferentiated and differentiated FLC with di-M-PGE2 (1 jug/ml) did not alter rates
of tumour appearance or growth, but increased the median survival of DBA/2J mice.
Systemic administration of di-M-PGE2 (10 1kg/mouse/day) was not toxic to the mice,
but significantly inhibited tumour growth and increased median survival in mice
injected s.c. with undifferentiated FLC. These effects of di-M-PGE2 were much more
pronounced in mice receiving differentiated (DMSO-treated) FLC. Inthislattergroup,
the appearance oftumour was also significantly delayed by di-M-PGE2. The different
effects of di-M-PGE2 treatment on tumours derived from undifferentiated and
differentiated cells suggest that the analogue is acting directly on tumour-cell
replication rather than on factors related to the host response.
PROSTAGLANDINS of the E series are
known to inhibit the growth of a number
of tumour cell lines (Hamprecht et al.,
1973; Thomas et al., 1974) in vitro. In
previous studies we demonstrated that
16,16-dimethyl-PGE2-methyl ester (di-
M-PGE2), a long-acting synthetic analogue
of PGE2, profoundly inhibited the growth
of B16 melanoma both in vitro and in vivo
(Santoro et al., 1976; 1977a). PGEs have
also been shown to induce differentiation
in some tumour-cell lines, including neuro-
blastomas (Prasad, 1972a and b) and
mouse fibroblasts (Johnson & Pastan,
1971).
Murine erythroleukaemia cells infected
with the Friend virus (FLC) differentiate
in vitro from a proerythroblast-like to a
normoblast-like stage producing haemo-
globin when they are treated with di-
methylsulfoxide (DMSO) or other inducers
(Friend et al., 1971; Leder & Leder, 1975;
Reuben et al., 1976; Ebert et al., 1976).
Chemically induced differentiation is
promptly and spontaneously reversed
when the inducing agents are removed
from the culture medium (Friend et al.,
1971).
The i.v. inoculation of cultured FLC
into DBA/2J mice produces malignant
disease, characterized by leukaemic-cell
infiltration of marrow, lymph nodes,
liver and spleen (Preisler et al., 1976)
whilst s.c. administration produces s.c.
tumours similar to myeloblastomas, which
cause the death of the animals within a
3-7-week period. Inoculation of mice with
FLC pretreated in vitro with DMSO for at
least 72 h produces smaller tumours and
permits longer survival than untreated-
cell inocula (Friend et al., 1971; Preisler
et al., 1976). In a recent study we demon-
strated that endogenously synthesized
PGE was involved in the regulation of the
proliferation and differentiation of FLC
in vitro (Santoro et al., 1979). Moreover,
the addition of the long-acting analogue
di-M-PGE2 to the culture medium pro-PROSTAGLANDIN ANI) FRIEND ERYTHROLEUKAEMIA J.V V[0 V)
fouiidly inhibited the growth and stimu-
lated the differentiation (measured as
haemoglobin production) ofDMSO-treated
cells. The effect of prostaglandins Aas
reversible; haemoglobin synthesis started
to decrease shortly after removal of
di-M-PG'E2 from the culture medium,
reaching control values after 14 duplica-
tion cycles. In the current study we have
evaluated the effect of di-M-PGE2 on
the growth of both undifferentiated and
DMSO-treated FLC in vivo.
MATERIALS AND1 METHODS
Friend erythroleukaemia cells (Strain 745,
cell line GM-86 from the Institute for Medical
Research, Camden, N.J.) were gro'wn in
Dulbecco's modified Eagle medium supple-
mented with 15% foetal calf serum, penicillin
(100 u/ml) and streptomycin (0.1 mg/ml),
in a humidified 950o air: 5%0 CO2 atmosphere,
at 37+05°C. 16,16-dimethyl-PGE2-methyl
ester (di-M-PGE2) wvas kindly provided by the
Upjohn Company, Kalamazoo, Mich. Di-M-
PGE2 was dissolved in absolute ethanol,
maintained at -20°C and diluted to the de-
sired concentration in medium (for in vitro
administration) or 0.9%0 sterile NaCl (for
in vivo adnministration). Control and PGE-
containing media and diluents contained
identical concentrations of ethanol (0-00500
in media; 10% in diluents). Media were
sterilized by Millipore filtration. Cell numbers
were determined by counting by haemocyto-
meter; s.e. for 5-10 counts ofthe same cultures
varied 2-6%. Cell viability determined by
vital-dye exclusion (Trypan blue, 0.04%o)
ranged 97-100% and was not influenced by
the addition ofdi-M-PGE2, DMSO or ethanol
at the concentrations used. Haemoglobin wvas
measured from cell lysates using the technique
of Crosby & Furth (1956). Lysis of cells wsas
obtained by repeated (3 x ) freeze-thawings
of pellets of cells (2 x 106 cells) that hlad been
wa,shed twice in sterile 0-90 NaCl.
Eighty nine 4-month-old male DBA/2J
illice wrere weighed, shaved and injected s.c.
in theright flank with 0-2 ml ofsterile medium
containing 0 5 or lOx 106 viable FLC. Mice
were examined daily by palpation for tumour
appearcance, and when the tumours became
measurable (at least 2 mm in diameter) they
were measured daily in at least 2 dimen-
sions by Vernier caliper. The average of the
smnallest and largest diameters wNas calculated.
Statistical comparisons used a t test for un-
paired data; P values of <0 05 were con-
sidered significant. Curves of rates of appear-
ance of tumours and survival were compared
with the use ofthe sign test (Dixon & Massey,
1957) and a values of <0(05 were considered
significant.
RESULTS
Fig. I shows the rate of tumour appear-
ance (A) and survival (B) of mice injected
with 05 x 106 viable FLC derived from
cultures pretreated for a 96 h period with
DMSO (155% v/v), di-M-PGE2 (1 [g/ml),
or DMSO+di-M-PGE2, as well as control
cultures. At that time, >9000 of the
DM80-treated cells were benzidine posi-
tive, and the haemoglobin concentrations
were shown to be: 0 44+0 33 [kg/106 cells
for control; 0 55f0 13 pg/106 cells for
di-M-PGE2; 3-32±0-31 [kg/106 cells for
DMSO; 4-24+J0 31 Htg/lo6 cells for DMSO
+di-M-PGE2. DM80-treatment of the
cells produced the previously reported
24 h delay in tumour appearance. There
was Ino significant difference in rate of
tumour appearance between control and
di-M-PGE2- or DMSO- and DMSO+
di-M-PGE2-treated groups. However,
median survival was significantly in-
creased in mice inoculated with DMSO-,
di-M-PGE2- and DMSO+di-M-PGE2-
treated cells; survival among the latter
2 groups were not significantly different
(Fig. 2B).
In a separate experiment, FLC were
cultured in vitro for 96 h in control or
DMSO- (1I .50) containing medium. The
cells were washed, resuspended in fresh
medium without foetal calf serum and
used for injection (106 viable cells/mouse).
Twenty-five mice received DMSO-pre-
treated cells (GCroups III and IV) and 24
received the same number of untreated
cells (Groups I and II). Immediately after
the tumour inoculation, each group of
mice was randomly divided into 2 equal
groups and injected with either di-M-
PGE2 (10 Htg/day/mouse) (Groups II and
IV) or control diluent (CGroups I and III).
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Fie.. 1.-Effect of di-MN-PGE2 treatment in vitro on the tumorigenicity of undifferentiated and
differentiated FLC. FLC that had been pretreated for 96 h with DMSO (A A), di-M-PGE2
(A- A), DMSO+di-M-PGE2 (0 0) or conitrol diluent ( 0 *~), were washed, resuspended
in fresh medium and injected (5 x 105/mouse) s.c. into 4 groups of 10 mice each.
A. The rate of tumour appearance. In both DMSO and DMSO +di-M-PGE2 groups the appearance
of tumours was significantly delayed as compared to control (cx <0.-004).
B. Mouse survival data. Percent survival was significantly increased in di-M-PGE2 (04<0.02),
DMSO (a<0.-0.01), and di-M-PGE2-4DMSO (cw<0-001) groups as compared to control.
Injections were repeated daily, s.c. in 50o) weight change compared to other
the tumour area from Days I to 5, and treatment groups. The rate of tumour
i.p. from Days 6 to 21, to avoid direct appearance is illustrated in Fig. 2A. Mice
inoculation of the tumour. Di-M-PGE2 receiving DMSO-treated cells developed
treatment did not cause significant (P< tumours significantly later than those that
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FiG. 2. The effect of di-M-PGE2 treatment ini vivo on tumour appearance and survival of mice
injecte(d with undifferentiated or differentiated FLC injected s.c. (106/mouse). Treatment was
started on the same day. Control, * *; di-M-PGE2, A . A; DMSO, A--- A; DMSO+di-M-
PGE2, 0--- O
A. Rate of tumour appearance. Di-M-PGE2 treatment of mice inoculated with DMSO-treated cells
significantly delayed tumour appearance as compared to both control and DMSO-control (Both
cx< 0001).
B. Mouse survival. Percent survival was significantly increased in DMSO and di-M-PGE2 groups
as compared to control (oz<0 001 and <0 004 respectively), and in di-M-PGE2+DMSO group
as compared to DMSO control (a<OOOl).M. G. SANTORO AND B. M. JAFFE
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FIG. 3.-Effect of di-M-PGE2 treatment
on tumour growth. Control, O *;
DMSO-control, A-*-* A; DMSO+di-M-
PGE2, A- -A; di-M-PGE2, 0---- O-
A. As mean tumour diameteri s.e.
(* =P< 05).
B. As percent of measurable tumours
(smallest diameter > 2 mm).
received undifferentiated cells. Di-M-PGE2
treatment did not significantly alter
tumour appearance in mice injected with
control cells, while it greatly delayed the
appearance of tumours in mice that re-
ceived DMSO-treated cells (oc<0OOl com-
pared to both control and DMSO-control).
Two mice (17%) ofthis last group did not
get visible tumours, and these were the
only animals not to develop tumours.
After appearance, tumours grew rapidly
in a rather uniform spherical shape. Mean
tumour diameters are shown in Fig. 3A.
Because some ofthe tumours (particularly
in Group IV) were too small to be meas-
ured, they were notincluded in the growth-
rate data presented in Fig. 3A; the percent
ofmeasurable tumours (>2 mm diameter)
used in the calculations is plotted in
Fig. 3B. These data clearly show that
tumours derived by DMSO-pretreated
cells grow more slowly than those from
undifferentiated cells. Furthermore, di-
M-PGE2 treatment profoundly inhibited
the rates of tumour growth, particularly
in mice injected with differentiated cells.
In fact, until Day 17, 50% ofthe tumours
in this group were immeasurable (<2 mm
in diameter).
The survival data are presented in
Fig. 2B. Mice injected with DMSO-treated
cells survived much longer than those
injected with control (undifferentiated)
cells (median survival-46 days vs 31
days). In one mouse in the DMSO group,
the tumour completely regressed and the
mouse was still alive 4 months after
tumourinoculation. Di-M-PGE2 treatment
significantly increased survival in mice
that received either control or DMSO-
treated cells. Median survival was in-
creased by 7 days in Group II and by at
least 15 days in Group IV. Two ofthe mice
receiving DMSO-treated cells plus di-
M-PGE2 treatment were still alive with
no sign of the disease 4 months after
tumour inoculation.
DISCUSSION
These data clearly show that the
DMSO-induced differentiation in FLC is
accomplished with aloss intumorigenicity,
whether measured as delay in tumour
appearance, decrease in tumour size, or
increase in host survival. Pretreatment
of both differentiated and undifferentiated
cells in vitro with di-M-PGE2 did not
significantly alter either rates of tumour
appearance or tumour growth, but did
increase host survival. Di-M-PGE2 treat-
ment in vivo inhibited tumour growth and
increased survival in mice inoculated
with undifferentiated FLC. However, this
effect was much stronger in mice receiving
differentiated cells. In this last group,
di-M-PGE2 treatment also greatly delayed
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(and in some mice completely prevented)
the appearance of tumours. Since thiu
effect was not seen in mice inoculated with
undifferentiated cells, the data suggesi
that di-M-PGE2 acts directly on the
replication of tumour cells, rather than
on factors related to host response. It is
interesting that the in vitro studies (San-
toro et al., 1979) also demonstrated thai
DMSO-treated FLC are much more sensi-
tive to di-M-PGE2 than undifferentiated
cells. In fact, the latter were not affected
by di-M-PGE2, even at higher concentra-
tions (50 jg/ml).
The antitumour effect of di-M-PGE2-
treatment in vivo cannot be due to in-
creased host immunological response. In
fact, prostaglandins of the E series are
known to be immunosuppressive. The
same dose of di-M-PGE2 has been shown
to prolong the survival of mouse skin
allografts (Anderson & Jaffe, 1974) and
hamster-to-rat heart xenografts (Kakita
et al., 1975). In the B16 melanoma studies
in vivo we showed that daily administra-
tion of the same dose of di-M-PGE2 did
not produce changes in the density (mg/
mm3) or the number ofinflammatory celil
in the tumours nor in any histological
aspect ofthe tumour (Santoro et al., 1977b)
In fact, the only difference noted was a
dose-related decrease in mitotic index.
These observations further support the
hypothesis that di-M-PGE2 acts directly
on tumour-cell replication rather than on
host factors. Further study is necessary
to investigate the specific mechanisms of
the growth-inhibitory actions of PGE.
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